XNK Therapeutics is entering into a Phase II clinical study to treat patients with multiple myeloma using its leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa.
XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated by Karolinska Institutet. XNK will provide its novel autologous NK cell-based product to the study set to take place at the Karolinska University Hospital in Stockholm, Sweden.
“Performing this Phase II study together with Karolinska Institutet is an important step for XNK in its ambition to combat multiple myeloma,” says Johan Liwing, CEO of XNK Therapeutics. “Combining our efforts together with the present partners highlights just how far XNK has progressed with its patented technology platform.”
About the study
The study ISA-HC-NK compares XNK’s leading drug candidate combined with isatuximab vs isatuximab as a consolidation treatment following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.